Chief Scientific Officer
Alan Whitmore is Chief Scientific Officer at e-Therapeutics PLC. He moved from academia into biotech 12 years ago and has worked in both drug delivery and drug discovery.
Vice President, Head of Chemistry
Dr. Stephanos Ioannidis obtained his B.Sc. at King's College London in chemistry and biochemistry before moving to Imperial College London
Global Head of Application Science
Alister Campbell is the Global Head of Application Science at Dotmatics.
Senior Principle Scientist
Chris is a medicinal chemist working across Target ID and early discovery chemistry at Benevolent AI.
Davide Gianni currently leads the Functional Genomics team in Discovery Sciences (AZ) in Cambridge UK.
Javier is Chief Scientific Officer (CSO) and co-founder at ZeClinics. He is an expert in zebrafish biology and the exploitation of this animal model for drug discovery purposes.
Professor of Pharmaceutical Chemistry
In 2012 JH served as Chairman of the Institute of Pharmaceutical Sciences (IPW).
Director of Discovery Biology & Discovery Sciences
Rob has been at AstraZeneca since 2016 where he leads the Discovery Biology department part of the Innovative Medicines organisation.
Head of Compound Screening
Amaury E. Fernández-Montalván is the Head of Compound Screening at the SERVIER Research Institute since March 2018.
Director Molecular Interactions and Biophysics
Dr. Matthias Frech is currently the Head of the Department for Molecular Interaction and Biophysics (MIB) at Merck.
Nikolaus Krall is a Vienna, Austria based biotech entrepreneur with a passion for translating cutting edge innovation from bench to bedside.
Founder & CEO
Dr. Varshney’s research and development expertise are diverse, and encompasses physiology and medicine (DVM), computational biology and machine learning/artificial intelligence (ML/AI) (PhD).
Chief Scientific Officer
InterAx Biotech AG
Dr. Waldhoer has a 25+ year experience both in academia and industry in Europe and the US, working in early R&D project management and drug discovery.
Senior Research Fellow
Dr Jonathan S Mason is a Senior Research Fellow at Sosei Heptares for GPCR structure-based drug design and a Scientific Advisor to several innovative biotech companies
Director of Biology
Pilar holds a PhD in Pharmacy from the Universitat de Barcelona. Supported by a Fulbright Postdoctoral Fellowship she worked at Harvard Medical School and later at Duke’s University, Durham (USA).
Sr. Vice President – Discovery Services
Kenneth holds a Ph.D. in Synthetic Organic/Organometallic Chemistry from Massachusetts Institute of Technology and has pursued his Postdoctoral study in Natural product synthesis
Sr Vice President
As Senior Vice President, Drug Discovery and Platform Sciences, Vivek Vishnudas, oversees the development of experimental therapeutics from conception and drug discovery to first-in-human studies.
Quantitative Biology Center - QBiC
High-throughput technologies generate an ever increasing amount of biological and medical data
Director BD&L Research Platforms
In the new Sanofi R&D organization, H. Haag is responsible for sourcing and external business within the Lead Generation department and is a member of its leadership team.
University of Oxford
Open Chemical Tools for Discovery and Validation of novel Drug Targets.
Scientist and Biotech entrepreneur with a proven track record in envisioning and establishing a successful AI/biotech startup.
Dora Barna received her MSc degree in Chemistry in 2009, and PhD degree in Theoretical Chemistry in 2013 from the University of Szeged, Faculty of Science and Informatics, in Hungary.
Global Head of Computer-Aided Drug Discovery
José is Global Head of Computer Aided Drug Discovery (CADD), part ofGlobal Discovery Chemistry at the Novartis Institutes for BioMedicalResearch (NIBR).
VP Novel Target Biology and Genomics
Alun is currently VP Novel Target Biology and Genomics at C4X Discovery. He has over 35 years experience in pharmaceutical R&D, including drug discovery and genetics research.
Global Head, External Innovation, Drug Discovery Platforms
Experienced leader and manager in complex cross-functional R&D and BD organisations of top pharmacompanies
Attorney At Law
Hanneke is the only lawyer-pharmacist in the Netherlands. She specializes in EU and national (bio)pharma law.
VP of Research
Philip Tagari is currently Vice President of Research (Therapeutic Discovery) at Amgen Inc, the world’s largest independent biotechnology company.
Dr. Martin Akerman is a data scientist trained in biology and computer science with a PhD from Technion (Israel) and a post doctorate from Cold Spring Harbor Laboratory (CSHL).
Director of UK Chemistry and IP
Paul Beswick is a Medicinal Chemist with over 30 years experience both in industry and university drug discovery groups.
Chief Technology Officer
Markus is a data scientist with a background functional genetic screening, engineering and bioinformatics and is leading the screening group and bioinformatics team at PhoreMost